Cory Renauer
Value, research analyst, biotech, small-cap

Peregrine Pharmaceuticals: Good Looking, But Still Single

Peregrine Pharmaceuticals (NASDAQ:PPHM) is a not yet profitable biotech based in Tustin, California. The company's pipeline consists of first-in-class monoclonal antibodies with a main focus on cancer treatment and imaging. Its three lead programs are in clinical trials for seven separate indications. Peregrine's wholly owned subsidiary, Avid Biosciences, generates enough revenue to partially offset the company's substantial clinical development costs.

Phosphatidylserine-targeting therapy, a new approach to fighting solid tumors

If you can remember your high school biology, you know that cell membranes are mainly composed of a phospholipid bilayer. The water soluble, or hydrophilic, "heads" of newly formed phospholipids face the inside of the cell with their hydrophobic "tails" pointed toward the center of the bilayer. Conversely, the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details